The Latest Breaking News from Gilead

As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

The Handmaid's Tale season 6 returns to Hulu on April 8 – here's everything we know about the dystopian drama's return.

Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.

March S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President Donald Trump and looked ahead to Federal Reserve Chair Jerome Powell’s congressional testimony as well as Wednesday’s release…

Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook.

Gilead Sciences is likely to report its fiscal fourth-quarter earnings next month, and analysts are expecting a modest fall in its earnings.

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

If GILD stays below 100, the investor can continue selling call options until the shares get called away.

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).